Celanese Corp (CE) · Nov 2, 2026 · Earnings
Beat — adj. EPS $1.65 vs ~$1.56 consensus
Celanese earnings beat EPS expectations and raised 2026 free-cash-flow guidance, but weak volumes left revenue below consensus.
Celanese is executing a debt-heavy turnaround: shifting toward higher-margin medical, electronics, and downstream materials while using cost cuts, divestitures, and cash generation to reduce leverage. This quarter advances that plan, but the operating recovery is still uneven.
The earnings beat came with a revenue-quality caveat. Adjusted EPS of $1.65 exceeded the published consensus of roughly $1.56, but $2.556 billion of revenue was below the roughly $2.62 billion consensus. Revenue rose 6% year over year because pricing more than offset a 4% volume decline; the headline earnings result therefore reflects mix, pricing, and productivity more than broad-based demand growth. The company said, “Today, we reported third quarter 2026 adjusted earnings per share of $1.65,” while the financial tables show Q3 revenue of $2,556 million versus $2,419 million a year earlier. 〔0〕
| Metric | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Adjusted EPS (Prepared remarks) | $1.65 (+23%) | $1.34 | ~$1.56 |
| Revenue (Table 4b) | $2,556M (+6%) | $2,419M | ~$2,620M |
| Adjusted EBIT (Table 1) | $367M (+13%) | $326M | |
| Free cash flow (Cash flow table) | $461M (+23%) | $375M | |
| Net debt (Balance sheet table) | $10,183M (-11%) | $11,414M |
Cash conversion is the clearest positive change. Third-quarter free cash flow reached $461 million, helped by a $184 million working-capital inflow, and management raised full-year 2026 free-cash-flow guidance to $750 million–$800 million. That directly supports the deleveraging story: net debt fell to $10.2 billion from $11.4 billion a year earlier, while year-end leverage is expected at about 4.7x. “Free cash flow for the quarter was $461million and brings the year-to-date total to more than $600million.”
The portfolio shift is working, but demand is not yet broad. Engineered Materials’ adjusted EBIT rose 5% year over year, or about 9% excluding Micromax, as medical sales grew 16% and electronics sales 30%; those higher-value markets helped offset automotive weakness, lower volumes, inflation, and logistics costs. Acetyl Chain adjusted EBIT increased more than 25%, but management expects both segments to moderate sequentially in the fourth quarter because of seasonality and continued soft demand conditions.
The outlook improves cash generation more than near-term growth visibility. EPS guidance of $6.00–$6.25 remains intact, while the raised cash-flow range and planned $152 million Nutrinova proceeds strengthen debt repayment capacity. The remaining issue is execution: the company still carries 4.9x net debt-to-operating EBITDA and expects $20 million of fourth-quarter inventory absorption tied to nylon optimization.
Bottom line: Celanese delivered an earnings beat and a meaningful cash-flow upgrade, strengthening the turnaround and deleveraging story. But the revenue miss and falling volumes keep this from being a clean acceleration signal; the improvement is real, yet still driven more by mix, pricing, and execution than by broad demand recovery.
December investor strategy and technology update
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!